NIH RECOVER Tissue Pathology: Understanding the Long-Term Impact of COVID-19
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Stuart Katz, MD · PRINCIPAL_INVESTIGATOR · NYU Langone Health
- Leora Horwitz, MD · PRINCIPAL_INVESTIGATOR · NYU Langone Health
- Andrea Troxel, ScD · PRINCIPAL_INVESTIGATOR · NYU Langone Health
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Number of decedents with presence of inflammationMonth 24
In decedents with acute SARS-CoV-2 infection (dying 15-30 days after infection), and in decedents with prior SARS-CoV-2 infection (who die more than 30 days after initial onset, in-hospital and out-of-hospital) with and without PASC.
- Number of decedents with presence of fibrosisMonth 24
In decedents with acute SARS-CoV-2 infection (dying 15-30 days after infection), and in decedents with prior SARS-CoV-2 infection (who die more than 30 days after initial onset, in-hospital and out-of-hospital) with and without PASC.
- Number of decedents with presence of thrombosisMonth 24
n decedents with acute SARS-CoV-2 infection (dying 15-30 days after infection), and in decedents with prior SARS-CoV-2 infection (who die more than 30 days after initial onset, in-hospital and out-of-hospital) with and without PASC.
- Number of decedents with presence of necrosisMonth 24
In decedents with acute SARS-CoV-2 infection (dying 15-30 days after infection), and in decedents with prior SARS-CoV-2 infection (who die more than 30 days after initial onset, in-hospital and out-of-hospital) with and without PASC.